{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:41:07Z","timestamp":1792140067893,"version":"4.4.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention & Research Institute of Texas","doi-asserted-by":"crossref","award":["RP210868"],"award-info":[{"award-number":["RP210868"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention & Research Institute of Texas","doi-asserted-by":"crossref","award":["RR180044"],"award-info":[{"award-number":["RR180044"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA200539"],"award-info":[{"award-number":["CA200539"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA214811"],"award-info":[{"award-number":["CA214811"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA239255"],"award-info":[{"award-number":["CA239255"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA278787"],"award-info":[{"award-number":["CA278787"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA282099"],"award-info":[{"award-number":["CA282099"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA2855209"],"award-info":[{"award-number":["CA2855209"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,11,13]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cancer immunotherapy using immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, patients with multiple myeloma (MM) rarely respond to ICB. Accumulating evidence indicates that the complicated tumor microenvironment (TME) significantly impacts the efficacy of ICB therapy. Therefore, investigating how TME components in MM influence ICB treatment is urgent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We employed two well-established murine myeloma models, 5TGM1 and Vk*MYC, by intravenously injecting 5TGM1 or Vk*MYC cells into mice, respectively, to determine ICB therapeutic efficacy in MM. Total mouse IgG or Ig2b ELISA or QuickGel split beta SPE kits and in vivo bioluminescent imaging were used to monitor MM tumor burden. Cytometry by time of flight (CyTOF) was used to quantify MM TME components. T cell proliferation and function were detected using flow cytometry. Peptide-Fc fusion proteins were used to deplete myeloid-derived suppressor cells (MDSCs). MM<jats:sup>DTR<\/jats:sup>, Foxp3<jats:sup>DTR<\/jats:sup>, CD4 KO and CD8 KO mice were used to elucidate the underlying mechanisms. Gene expression levels in human MM were analyzed using Gene Expression Omnibus public datasets.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found that programmed cell death protein 1 (PD-1) antibody treatment had a therapeutic effect in 5TGM1 mice; it was ineffective in Vk*MYC mice. CyTOF indicated that the bone marrow (BM) of both models was inflamed, suggesting that immune suppressive cells might be inhibiting the reactivation of T cells in the BM. We observed higher numbers of MDSCs, regulatory T (Treg) cells, and tumor-associated macrophage (TAMs) in myeloma BM compared with that of tumor-free mice. Specifically, depleting MDSCs, but not Treg cells or TAMs, sensitized Vk*MYC mice and enhanced the response of 5TGM1 mice to PD-1 ICB, which was dependent on CD8<jats:sup>+<\/jats:sup> but not CD4<jats:sup>+<\/jats:sup> T cells. MDSCs, especially M-MDSCs and CD84<jats:sup>+<\/jats:sup> MDSCs, significantly inhibited the activation and cytotoxic cytokine production of CD8<jats:sup>+<\/jats:sup> T cells in vitro. Moreover, database profiling of patient BM revealed a negative correlation between MDSCs signature genes and cytotoxic CD8<jats:sup>+<\/jats:sup> T cell signature genes, with post-maintenance patients with myeloma displaying a higher ratio of cytotoxic CD8<jats:sup>+<\/jats:sup> T cell to MDSCs signature genes compared with pretreated patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study highlights the potential of MDSCs depletion in enhancing the sensitivity of patients with myeloma to PD-1 ICB therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-008979","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:13:33Z","timestamp":1736147613000},"page":"e008979","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8087-5047","authenticated-orcid":false,"given":"Wei","family":"Xiong","sequence":"first","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3013-4523","authenticated-orcid":false,"given":"Liuling","family":"Xiao","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"},{"name":"First Affiliated Hospital, School of Basic Medicine, Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Duan","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Xian","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Su","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8954-7007","authenticated-orcid":false,"given":"Yabo","family":"LI","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhong","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Qian","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-3398","authenticated-orcid":false,"given":"Qing","family":"Yi","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"2025100311350268000_13.1.e008979.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"2025100311350268000_13.1.e008979.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020"},{"key":"2025100311350268000_13.1.e008979.3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.2020009856","article-title":"RAR\u03b3 activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"2025100311350268000_13.1.e008979.4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/leu.2017.193","article-title":"Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma","volume":"32","author":"Wang","year":"2018","journal-title":"Leukemia"},{"key":"2025100311350268000_13.1.e008979.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01269-5","article-title":"A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors","volume":"15","author":"Su","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025100311350268000_13.1.e008979.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2025100311350268000_13.1.e008979.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.005"},{"key":"2025100311350268000_13.1.e008979.8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.immuni.2018.06.003","article-title":"Immune Checkpoint Blockade across the Cancer Care Continuum","volume":"48","author":"Helmink","year":"2018","journal-title":"Immunity"},{"key":"2025100311350268000_13.1.e008979.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.02.015"},{"key":"2025100311350268000_13.1.e008979.10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00277-017-3176-6","article-title":"PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas","volume":"97","author":"Wang","year":"2018","journal-title":"Ann Hematol"},{"key":"2025100311350268000_13.1.e008979.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x"},{"key":"2025100311350268000_13.1.e008979.12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153247","article-title":"IL-9\/STAT3\/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity","volume":"132","author":"Xiao","year":"2022","journal-title":"J Clin Invest"},{"key":"2025100311350268000_13.1.e008979.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0273-y"},{"key":"2025100311350268000_13.1.e008979.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00931-3"},{"key":"2025100311350268000_13.1.e008979.15","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J Clin Invest"},{"key":"2025100311350268000_13.1.e008979.16","article-title":"CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma","volume":"6","author":"Lewinsky","year":"2021","journal-title":"JCI Insight"},{"key":"2025100311350268000_13.1.e008979.17","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1172\/JCI121421","article-title":"E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs","volume":"128","author":"Bi","year":"2018","journal-title":"J Clin Invest"},{"key":"2025100311350268000_13.1.e008979.18","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0148"},{"key":"2025100311350268000_13.1.e008979.19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41375-021-01301-6","article-title":"Targeting LAG3\/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma","volume":"36","author":"Bae","year":"2022","journal-title":"Leukemia"},{"key":"2025100311350268000_13.1.e008979.20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI77181"},{"key":"2025100311350268000_13.1.e008979.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1553"},{"key":"2025100311350268000_13.1.e008979.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094417"},{"key":"2025100311350268000_13.1.e008979.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.01.007"},{"key":"2025100311350268000_13.1.e008979.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0994-6","article-title":"Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma","volume":"14","author":"Cooke","year":"2016","journal-title":"J Transl Med"},{"key":"2025100311350268000_13.1.e008979.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-412783"},{"key":"2025100311350268000_13.1.e008979.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3905"},{"key":"2025100311350268000_13.1.e008979.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306"},{"key":"2025100311350268000_13.1.e008979.28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.310"},{"key":"2025100311350268000_13.1.e008979.29","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.79"},{"key":"2025100311350268000_13.1.e008979.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02178-3"},{"key":"2025100311350268000_13.1.e008979.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.02.007"},{"key":"2025100311350268000_13.1.e008979.32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130903"},{"key":"2025100311350268000_13.1.e008979.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026317","article-title":"Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits","volume":"6","author":"Erblich","year":"2011","journal-title":"PLoS One"},{"key":"2025100311350268000_13.1.e008979.34","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151"},{"key":"2025100311350268000_13.1.e008979.35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061852"},{"key":"2025100311350268000_13.1.e008979.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.02.005"},{"key":"2025100311350268000_13.1.e008979.37","doi-asserted-by":"crossref","DOI":"10.1177\/11795549211035540","article-title":"Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects","volume":"15","author":"Li","year":"2021","journal-title":"Clin Med Insights Oncol"},{"key":"2025100311350268000_13.1.e008979.38","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3560"},{"key":"2025100311350268000_13.1.e008979.39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"2025100311350268000_13.1.e008979.40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003323","article-title":"Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials","volume":"17","author":"Danziger","year":"2020","journal-title":"PLoS Med"},{"key":"2025100311350268000_13.1.e008979.41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448548"},{"key":"2025100311350268000_13.1.e008979.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1410626111"},{"key":"2025100311350268000_13.1.e008979.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0741"},{"key":"2025100311350268000_13.1.e008979.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.03.033"},{"key":"2025100311350268000_13.1.e008979.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200"},{"key":"2025100311350268000_13.1.e008979.46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/cancers13020164","article-title":"PD-L1\/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression","volume":"13","author":"Costa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100311350268000_13.1.e008979.47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002371","article-title":"Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor","volume":"9","author":"Curti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100311350268000_13.1.e008979.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y"},{"key":"2025100311350268000_13.1.e008979.49","first-page":"3128","article-title":"Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody","volume":"59","author":"Onizuka","year":"1999","journal-title":"Cancer Res"},{"key":"2025100311350268000_13.1.e008979.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.03.013"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-008979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:35:12Z","timestamp":1759516512000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-008979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,4]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-008979"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-008979","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}